Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jülg

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Infection|June 29, 2006
Treatment interruption in HIV therapy: a SMART strategy?B Jülg, F D Goebel
Infection|August 11, 2005
HIV genetic diversity: any implications for drug resistance?B Jülg, F D Goebel
Infection|November 1, 2005
What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?B Jülg, F D Goebel
Infection|June 9, 2005
Susceptibility to HIV/AIDS: an individual characteristic we can measure?B Jülg, F D Goebel
Infection|October 13, 2006
Clinical news from the XVI International AIDS Conference: The attempt of a summing upB Jülg, F D Goebel
Journal of Virus Eradication|August 3, 2016
Novel immunological strategies for HIV-1 eradicationB Jülg, D H Barouch
Infection|November 1, 2005
What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?B Jülg, F D Goebel
European Journal of Medical Research|March 21, 2007
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patientsG J Claas, B Jülg, F D Goebel, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Infection|June 29, 2006
Treatment interruption in HIV therapy: a SMART strategy?B Jülg, F D Goebel
Infection|August 11, 2005
HIV genetic diversity: any implications for drug resistance?B Jülg, F D Goebel
Infection|November 1, 2005
What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?B Jülg, F D Goebel
Infection|June 9, 2005
Susceptibility to HIV/AIDS: an individual characteristic we can measure?B Jülg, F D Goebel
Infection|October 13, 2006
Clinical news from the XVI International AIDS Conference: The attempt of a summing upB Jülg, F D Goebel
Journal of Virus Eradication|August 3, 2016
Novel immunological strategies for HIV-1 eradicationB Jülg, D H Barouch
Infection|November 1, 2005
What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?B Jülg, F D Goebel
European Journal of Medical Research|March 21, 2007
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patientsG J Claas, B Jülg, F D Goebel, et al.
Pageof 1